Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; S. 1264 - Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.
Issues relating to Intellectual Property protections.
Duration: December 1, 2014
to
present
General Issues: Medicare/Medicaid , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Health Issues , Copyright/Patent/Trademark , Pharmacy
Spending: about $1,900,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Executive Office of the President (EOP), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jonathon Jones
Legislative Director, Senator Carper
Chief of Staff, Senator Carper
Justin McCarthy
Legislative Correspondent, Rep. Thomas Ewing
Legislative Assistant, Rep. Thomas Ewing
Assist. USTR, Intergovernmental and Pub. Affairs
Assistant USTR, Congressional Affairs
Special Assistant to the President, Leg. Affairs
Andrew McKechnie
Health Policy Advisor, Sen. Finance Committee
Legislative Assistant, Senator Norm Coleman
Legislative Assistant, Rep. Jim Ramstad
Bipartisan Medical Technology Caucus
Corey Malmgren
Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010)
John Michael Gonzalez
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 12.
Original Filing: 301548465.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; S. 1264 - Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 16.
Original Filing: 301524982.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; S. 1264 - Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual property protections.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 16, 2023.
Original Filing: 301501629.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; S. 1264 - Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual property protections.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301482044.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform, Issues related to Anti-Microbial Resistance (AMR).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for COVID-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax policy.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to antimicrobial resistance. H.R. 3932/S. 2076 - The PASTEUR Act of 2021. Consolidated Appropriations Act, 2023 (PL 117-328).
1st Quarter, 2023
In Q1, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301460151.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for COVID-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax policy.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 14, 2023.
Original Filing: 301427656.xml
Lobbying Issues
S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Consolidated Appropriations Act, 2023 (PL 117-328), Division FF, Title III - Food and Drug Administration, Subtitle B - Drugs and Biologics and Subtitle F, Chapter 1 - Clinical Trial Diversity and Modernization; H.R. 7559 - the Prescription Information Modernization Act; Package Inserts/eLabeling Issues (H.R. 7559 - Prescription Information Modernization Act of 2022).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 16, 2022.
Original Filing: 301404976.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S. 2199 - Insulin Price Reduction Act; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; The Continuing resolution and Ukraine Supplemental Appropriations Act 2023 (PL 117-180), Division F - FDA User Fee Reauthorization Act of 2022; H.R. 7559 - the Prescription Information Modernization Act; Package Inserts/eLabeling Issues (H.R. 7559, Prescription Information Modernization Act of 2022).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5376 - Build Back Better, Subtitle J; Inflation Reduction Act of 2022 (PL 117-169), Subtitle B - Prescription Drug Pricing Reform; issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 15, 2022.
Original Filing: 301381496.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S.2199 - Insulin Price Reduction Act; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Issues related to the deployment of COVID treatments.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Lobbying Issues
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 15, 2022.
Original Filing: 301357238.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Issues related to the development of COVID treatments; H.R. 6833/S. 3700 - Affordable Insulin Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 15, 2022.
Original Filing: 301323307.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 5260 - Reduced Costs and Continued Cures Act; issues related to the development of COVID treatments.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
S. 1435 - Affordable Prescriptions for Patients Act of 2021; H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301014.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 5260 - Reduced Costs and Continued Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
S. 1435 - Affordable Prescriptions for Patients Act of 2021; H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, Tiber Creek Group lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 17, 2021.
Original Filing: 301278601.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
S. 1435 - Affordable Prescriptions for Patients Act of 2021; H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 17, 2021.
Original Filing: 301255361.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform; Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs; H.R. 1319 - American Rescue Plan Act of 2021, SEC. 9816, SUNSET OF LIMIT ON MAXIMUM REBATE AMOUNT FOR SINGLE SOURCE DRUGS AND INNOVATOR MULTIPLE SOURCE DRUGS.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236176.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 4100/S 1712, DISARM Act; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; Executive Order on Lowering Drug Prices by Putting America First; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; Issues related to the Medicaid Drug Rebate Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222008.xml
Lobbying Issues
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; Executive Order on Lowering Drug Prices by Putting America First
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301199714.xml
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301178726.xml
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the United States-Mexico-Canada-Agreement (USMCA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 17, 2020.
Original Filing: 301110418.xml
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R.1865 Further Consolidated Appropriations Act, 2020 (Public Law No: 116-94)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R.1865 Further Consolidated Appropriations Act, 2020 (Public Law No: 116-94)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the United States-Mexico-Canada-Agreement (USMCA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077983.xml
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the United States-Mexico-Canada-Agreement (USMCA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301057439.xml
Lobbying Issues
Issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301036777.xml
Lobbying Issues
Issues related to vaccines; Issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. Provisions relating to the Part D Pricing Reform. Proposal to eliminate medicaid inflationary cap. Issues relating to biosimilars coverage & pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009278.xml
Lobbying Issues
Issues related to vaccines; issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. Provisions relating to the Part D coverage gap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997018.xml
Lobbying Issues
Issues related to vaccines; issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. Provisions relating to the Part D coverage gap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300975192.xml
Lobbying Issues
Issues related to vaccines; issues related to pharmaceutical pricing and transparency; issues related to the Hospital Outpatient Prospective Payment System final rule.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. P.L. 115-123 - Bipartisan Budget Act of 2018, provisions relating to the Part D coverage gap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2018.
Original Filing: 300954633.xml
Lobbying Issues
Issues related to vaccines, S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency.Issues related to the Hospital Outpatient Prospective Payment System final rule.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency. P.L. 115-123 - Bipartisan Budget Act of 2018, provisions relating to the Part D coverage gap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933977.xml
Lobbying Issues
Issues related to vaccines, S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency. S. 934 - FDARA, HR 1409 - FDARA. S. 1348 - SPIKE Act of 2017. S. 1827 Keep Kids Insurance Dependable and Secure (KIDS) Act of 2017. HR 3921- Helping Ensure Access for Little Ones, Toddlers and Hopeful Youth by Keeping Insurance Delivery Stable Act of 2017. Issues related to the Hospital Outpatient Prospective Payment System final rule.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911643.xml
Lobbying Issues
Issues related to vaccines, S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency. S. 934 - FDARA, HR 1409 - FDARA. S. 1348 - SPIKE Act of 2017. S. 1827 Keep Kids Insurance Dependable and Secure (KIDS) Act of 2017. HR 3921- Helping Ensure Access for Little Ones, Toddlers and Hopeful Youth by Keeping Insurance Delivery Stable Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300892231.xml
Lobbying Issues
Issues related to vaccines, S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency. S. 934 - FDARA, HR 1409 - FDARA. S. 1348 - SPIKE Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing and transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300873026.xml
Lobbying Issues
Issues related to vaccines, S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing, S.Amdt.134 to S.Con.Res.3 A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854826.xml
Lobbying Issues
Issues relating to vaccines. Issues related to drug pricing. 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2016
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300835046.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2016
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300817468.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2016
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300802098.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2015
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300779388.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2015
In Q3, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762340.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D. Part B reimbursement and coding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2015
In Q2, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300745637.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on April 20, 2015.
Original Filing: 300727545.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medicare reimbursement. Low-income subsidy in Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2014
In Q4, Peck Madigan Jones lobbied for Merck & Co., Inc , earning $50,000. The report was filed on Jan. 20, 2015.
Original Filing: 300706523.xml
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Trade Promotion Authority. Trans-Pacific Partnership.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2014
Peck Madigan Jones filed a lobbying registration on Jan. 8, 2015 to represent Merck & Co., Inc, effective Dec. 1, 2014.
Original Filing: 300693564.xml
Issue(s) they said they’d lobby about: Issues relating to vaccines; Medicare reimbursement; Trade Promotion Authority; Trans-Pacific Partnership. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate